Background {#Sec1}
==========

Prostate cancer (PCa) is the most common newly diagnosed cancer in males, with 1.6 million new cases per year; PCa is the third most common cause of cancer-related death in men \[[@CR1]\]. Despite the use of radical prostatectomy (RP) and radiotherapy (RT) as initial therapies for localized PCa, approximately 18 % of patients eventually experience biochemical recurrence (BCR) \[[@CR2]\]. Therefore, it is crucial to identify the patients who are at an increased risk of BCR after RP or RT. Preoperative prostate-specific antigen (p-PSA) levels \[[@CR3]\], Gleason score (GS) \[[@CR4]\] and pathological stage \[[@CR5]\] are widely used as traditional risk factors for BCR. However, there is a growing interest in the identification of a new prognostic marker to improve the evaluation of the likelihood of BCR in PCa patients after local treatment.

Perineural invasion (PNI), which is considered a major mechanism for the extraprostatic spread of PCa \[[@CR6]\], has been increasingly recognized as a novel prognostic marker \[[@CR7]\]. However, whether PNI might be a prognostic factor for BCR is still under debate \[[@CR8]\]. Some authors suggest that the presence of PNI is associated with adverse oncological outcomes and a higher risk of BCR, whereas others argue that PNI is not an independent predictor of BCR.

Therefore, to further clarify the relationship between PNI and the risk of BCR in PCa, we performed this systematic review and meta-analysis to evaluate whether the presence of PNI has a prognostic impact on BCR in patients following RP or RT.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

According to the PRISMA guidelines \[[@CR9]\], a systematic literature search of the PubMed, EMBASE, Chinese National Knowledge Infrastructure (CNKI) and Wan Fang databases was performed (up to May 2017). The search strategy used the following: ("prostate cancer" or "prostate AND neoplasms") and ("radical prostatectomy" or "radiotherapy") and ("perineural invasion") and ("biochemical recurrence"). We also manually searched for potentially relevant studies from the references listed in the selected review articles. The language of the publications was limited to English and Chinese.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

The inclusion criteria for the eligible studies were as follows: (1) all patients were diagnosed with histologically confirmed PCa, and PNI in RP specimens and biopsy specimens were assessed by pathologists; (2) all patients underwent RP or RT; (3) BCR after RP was defined as a detectable or rising PSA value after surgery that was ≥0.2 ng/ml with a second confirmation (American Urological Association \[[@CR10]\]) ; BCR after RT was defined as a rise in PSA level of ≥2 ng/ml above the nadir (American Society for Radiation Oncology and Radiation Therapy Oncology Group in Phoenix \[[@CR11]\]); (4) the risk of BCR was estimated as hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) or the risk could be calculated from the original articles; (5) the study was of a prospective or retrospective cohort design; (6) the articles were published in English or Chinese. The exclusion criteria were as follows: (1) letters, reviews, case reports, editorials and author responses; (2) non-human studies; (3) studies that did not analyze the outcome after PNI and BCR; (4) duplicate articles; (5) articles contained elements that were inconsistent with the inclusion criteria.

Data extraction and Study Quality {#Sec5}
---------------------------------

The data of the eligible studies were extracted independently by two investigators (Zhen-lei Zha and Wei Qu). Any discrepancies were resolved by discussion with a third reviewer (Hu Zhao). The following data were extracted from the included studies: first author, year of publication, country, recruitment period, sample size, patient's age, preoperative PSA level, Gleason score, pathological stage, positive percentage of PNI, definition of BCR, follow-up time and the HR(95%CI) of PNI for BCR. When the study provided the results of both the multivariate and univariate outcomes, we chose the multivariate model. The quality of the eligible studies was evaluated according to the Newcastle-Ottawa scale (NOS) \[[@CR12]\], which include 3 domains with 8 items. Studies with scores of 7 or more stars were considered high- quality studies.

Statistical analyses {#Sec6}
--------------------

All statistical analyses in this meta-analysis were performed by Stata 12.0 software (Stat Corp, College Station, TX, USA).The association between PNI and BCR outcome was presented as summary relative risk estimates (SRREs) and 95% CIs. Heterogeneity between studies was assessed using Q and I^2^ statistics. P \< 0.10 or I^2^ \> 50% was considered significant heterogeneity. A random effects model was used when obvious heterogeneity was observed, but otherwise, a fixed-effects model was used. Sensitivity analysis was used to estimate the reliability of the pooled results via the sequential omission of each study. Subgroup analyses were performed to examine potential sources of heterogeneity according to the adjusted parameters. Publication bias was assessed by funnel plots and was statistically determined by Begg's tests; a *p* value \< 0.05 was considered statistically significant.

Results {#Sec7}
=======

Search results {#Sec8}
--------------

The search and selection process for eligible studies is shown in Fig. [1](#Fig1){ref-type="fig"}. In all, 222 articles were initially identified. Among them, 73 duplicates were excluded. After the abstracts were screened, 93 articles were excluded for the following reasons: non-human studies, letters, case reports, reviews, and other obvious irrelevant studies. A further 37 articles were excluded after full-text review because the results did not reported PNI on the BCR. Finally, 19 retrospective cohort studies met our inclusion criteria and were included in the meta-analysis. Of these, 13 studies with 10,807patients were analyzed to investigate whether PNI acts as a predictive biomarker of BCR in PCa following RP. Six studies with 2,605 patients were evaluated to determine the relationship between PNI and the risk of BCR in PCa following RT.Fig. 1Flowchart of search and inclusion process for eligible studies

Characteristics of the included studies {#Sec9}
---------------------------------------

The main characteristics of the included studies are shown in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. All articles included were published in English, except for one, which was published Chinese \[[@CR13]\]. All studies were published between 2003 and 2017, and the median duration of follow-up varied from 18.4 to 108 months. Patients in these studies were all diagnosed with PCa and received RP (13 studies) or RT (6 studies). Of the 19studies, 9 originated in Asia, and 10 were conducted in the other regions (USA, Australia, Belgium, Canada). This meta-analysis was based on a total sample size of 13,412 patients, of which 4,197 patients were reported to have PNI. Regarding the GS, 8,306 patients presented with a GS ≥7. For quality evaluated by the NOS, all the studies were found to be of high quality.Table 1Characteristics of the included studies on PNI in patients with PCa following RPAuthorYearCountryRecruitment periodsample sizeAge (years)p-PSA (ng/ml)GS≥7 (n.%)Pathological stage ≥ pT2 (n.%)PNI (n.%)Follow-up (months)NOS (score)Ito et al. \[[@CR32]\]2003Japan1989-199882Mean 66.5Mean 17.247 (57.3%)50(61%)64 (78%)Mean 21.77Jeon et al. \[[@CR25]\]2009Korea1995-2004237Mean 64.5Mean 11.2183 (77.2%)237(100%)100 (42.2%)Median 21.68Lee et al. \[[@CR18]\]2010Korea1999-2010361Mean 69Mean 15.6160 (44.3%)361(100%)188 (52.1%)Mean 42.27Loeb et al. \[[@CR33]\]2010USA2002-20071256Mean 56.1Mean 5.7293 (23.3%)297(23.6%)188 (15%)Mean 33.68Muramaki et al. \[[@CR34]\]2010Japan2003-2007174Mean 67.5Mean 9.5150 (86.2%)128(73.6%)107 (83.6%)Median 44.37Jung et al. \[[@CR35]\]2011Korea2005-2009407Mean 63.2Mean 10.3247 (60.7%)307(75.4%)129 (31.7%)Median 18.47Lee et al. \[[@CR36]\]2015Korea2011-2012752Mean 66Mean 9.3605 (80.5%)260(34.6%)483 (64.2%)Mean 28.37Reeves et al. \[[@CR27]\]2015Australia2005-20121497Median 62NR1306 (87.2%)1173 (78%)1173 (78.4%)Median 147Watkins et al. \[[@CR37]\]2015USA2003-2010279Median 62Median 5.580 (28.7%)279(100%)193 (69%)Median 52.78Zhu et al. \[[@CR13]\]2016China2002-2014502Median 67Median 12.9248 (49.4%)502(100%)411 (81.9%)Median 28.67Kang et al. \[[@CR24]\]2016Korea2003-20142034Median 67Median 7.41726 (84.9%)NR252 (12.4%)Median 487Kim et al. \[[@CR38]\]2016Korea2005-20162316Median 65Median 7.41621 (69.9%)2316(100%)NRMedian 608Aoun et al. \[[@CR5]\]2017Belgium1990-2013910Mean 64Median 6.8189 (20.8%)910(100%)305 (33.5%)Median 1087GS: Gleason score; PNI: perineural invasion; NR: not reported;NOS: Newcastle--Ottawa Scale; p-PSA: preoperative PSATable 2Characteristics of the included studies on PNI in patients with PCa following RTAuthorYearCountryRecruitment periodsample sizeAge (years)p-PSA (ng/ml)GS≥7 (n.%)PNI (n.%)RadiotherapyFollow-up (months)NOS (score)Copp et al\[[@CR39]\]2005USA1997-200093Median 69.1Median 9.134(36.6%)17(18.3%)EBRTMedian 457Yu et al\[[@CR19]\]2007USA1993-2002657Mean 68NR238(36.2%)112 (19.1%)EBRTMedian 687Pina et al\[[@CR40]\]2010Canada1999-2008339Mean 61.9Mean 5.745(13.3%)89(26.3%)BTMedian 328Feng et al\[[@CR41]\]2011USA1998-2008718Median 69.4Median 8.3474(66%)220(34%)EBRTMedian 62.28Ding et al\[[@CR30]\]2012USA1998-2003185Median 69NR47(25.4%)10(5%)BT/ EBRTMedian 807Spratt et al\[[@CR42]\]2013USA1989-2011613Median 70NR613(100%)156(25.4%)EBRTMedian 727GS: Gleason score; PNI: perineural invasion; EBRT: external beam radiotherapy; BT: brachytherapy; NR: not reported; NOS: Newcastle--Ottawa Scale; p-PSA: preoperative PSA

Relationship between PNI and BCR after RP {#Sec10}
-----------------------------------------

The forest plots of the meta-analyses are shown in Fig. [2](#Fig2){ref-type="fig"}. A random effects model was applied because the heterogeneity was evident among these studies (*p*= 0.025, I^2^= 48.6%). The pooled HR indicated that the presence of PNI was associated with a higher risk of BCR in patients with PCa after RP (HR=1.23, 95% CI: 1.11, 1.36, *p*\<0.001). According to the sensitivity analysis, the SRRE ranged from 1.18 (95% CI: 1.09, 1.29) to 1.26 (95% CI: 1.14, 1.38) (Fig. [4a](#Fig4){ref-type="fig"}). In the subgroup analyses, we found that the heterogeneity was decreased significantly in some models, such as those of geographical region ("other regions") and, age \<65 years. It should also be noted that; the results of the subgroup analyses were consistent with the primary findings (Table [3](#Tab3){ref-type="table"}). Furthermore, no statistical evidence of publication bias was found as assessed by Begg's tests (*p* = 0.124) ( Fig. [5a](#Fig5){ref-type="fig"}).Fig. 2Forest plots for PNI and outcomes of BCR in PCa patients following RPTable 3Summary and subgroup analyses of the eligible studiesAnalysis specificationNo. of studiesStudy heterogeneityEffects modelPooled HR(95% CI)*P*-ValueI^2^(%)*P* ~heterogeneity~Radical prostatectomyOverall1348.60.025Random1.23 (1.11, 1.36)\<0.001Geographical region Asia957.80.013Random1.26 (1.10, 1.45)0.001 Other regions460.363Fixed1.23 (1.11, 1.36)0.027Age(years) ≥65767.20.006Random1.25 (1.04, 1.50)0.015 \<65600.425Fixed1.20 (1.08, 1.32)\<0.001p-PSA(ng/ml) ≥10444.40.126Fixed1.21 (1.01, 1.46)0.037 \<10857.80.027Random1.28 (1.10, 1.49)0.001Sample size(cases) ≥ 500745.70.101Fixed1.23 (1.03, 1.47)0.002 \< 500657.50.028Random1.24 (1.08, 1.41)0.026Median follow-up( months) ≥ 30734.90.162Fixed1.34 (1.12, 1.61)0.001 \< 30657.90.036Random1.16 (1.11, 1.36)0.014RadiotherapyOverall634.70.176Fixed1.22 (1.12, 1.34)\<0.001Age(years) ≥65444.80.143Fixed1.21 (1.11, 1.33)\<0.001 \<65238.80.201Fixed1.45 (0.93, 2.24)0.097Sample size(cases) ≥ 500300.495Fixed1.20 (1.09, 1.31)\<0.001 \< 500331.00.235Fixed1.68 (1.18, 2.39)0.004

Association between PNI and BCR following RT {#Sec11}
--------------------------------------------

As shown in Fig. [3](#Fig3){ref-type="fig"}, the pooled HR from 6 studies indicated that PNI was an independent risk factor for BCA in PCa following RT (HR=1.22, 95% CI: 1.12, 1.34, *p*\<0.001). Due to the lack of evidence of heterogeneity among the studies (*p*= 0.176, I^2^ = 34.7%), a fixed effects model was applied. The SRRE for BCR ranged from1.20 (95% CI: 1.07, 1.34) to 1.27(95% CI: 1.15, 1.42) according to the sensitivity analysis (Fig. [4b](#Fig4){ref-type="fig"}). The results of the subgroup analysis showed that PNI in a sample size ≥ 500 cases was significantly associated with BCR (n=3, HR=1.20, 95% CI: 1.09, 1.31, *p* \<0.001) (Table [3](#Tab3){ref-type="table"}). Begg's tests (*p* = 0.081) provided no evidence of substantial publication bias in these studies (Fig. [5b](#Fig5){ref-type="fig"}).Fig. 3Forest plots for PNI and outcomes of BCR in PCa patients following RTFig. 4**a**: Sensitivity analysis for PNI and BCR in PCa following RP; **b**: Sensitivity analysis for PNI and BCR in PCa following RTFig. 5**a**: Funnel plots and Begg's tests for the evaluation of publication bias in RP group; **b**: Funnel plots and Begg's tests for the evaluation of publication bias in RT group

Discussion {#Sec12}
==========

With the wide spread use of the serum PSA level in PCa screening, most patients with newly diagnosed PCa present with clinically localized or locally advanced disease \[[@CR14]\]. RP and RT have become the standard local treatments for localized PCa. However, approximately 1/3 of patients will develop BCR after RP, and 25\~33% will experience BCR after RT \[[@CR15]\]. Therefore, the characterization of the pathological features that may predict BCR is important for counseling patients and in directing the initial or adjuvant therapy. To date, seminal vesicle \[[@CR16]\], surgical margins and extracapsular extension \[[@CR17]\] are widely used as risk predictors of BCR in PCa. However, these are inferior and cannot accurately predict the risk of BCR in patients with PCa and complicated tumor backgrounds. Therefore, more sensitive and specific markers of risk are needed.

The phenomenon of peripheral nerve involvement has been overlooked for a long time, but it is now gaining recognition as a potential component of the cancer microenvironment \[[@CR18]\]. PNI is defined as cancer cell tracking along or around a nerve within the perineural space \[[@CR19]\]. It has been demonstrated that PNI may be a route of metastasis for many different cancers (pancreatic \[[@CR20]\], bladder \[[@CR21]\] and colorectal \[[@CR22]\]). Patients with PNI have a higher risk of extraprostatic extension detected at the time of RP \[[@CR23]\]; in other words, these patients have an increased risk of BCR.

However, the clinical significance of PNI in PCa following RP or RC is still controversial. Kang \[[@CR24]\] and Jeon \[[@CR25]\] showed that PNI is an adverse pathologic parameter and an independent predictor for BCR in PCa patients who undergo RP. Similarly, Yu \[[@CR19]\] and Wong \[[@CR26]\] considered that PNI is an independent risk factor associated with an increased risk of BCR in patients who undergo external beam radiotherapy. On the contrary, Reeves \[[@CR27]\] and Freedland \[[@CR28]\] reported that PNI is not correlated with extracapsular extension and BCR in PCa after RP. Nevertheless, Weight \[[@CR29]\] suggested that the presence of PNI is not a significant predictor of BCR in patients undergoing brachytherapy (BT) for PCa, and Ding\[[@CR30]\] demonstrated a significant independent association between PNI and an increased risk of biochemical failure in 185 PCa patients who received BT.

The conflicting results from different studies prompted us to perform this meta-analysis. For this study, we analyzed 19 studies that included 13,412 patients with PCa, of which 4,197 (31.2%) had PNI. Our results demonstrate that PNI was associated with a higher risk of BCR in PCa patients who underwent RP (p \<0.001) or RT (p \<0.001). These findings are similar to those reported by Kang \[[@CR24]\] and Yu \[[@CR19]\]. Notably, the overall findings in the present meta-analysis were consistently independent of geographical region, age, p-PSA, sample size, publication year, and follow-up in the RP group; the findings were also independent of age and sample size in the RT series. In the sensitivity analysis, we sequentially excluded each study, and the reliability and robustness of the results were confirmed. Moreover, no evidence of significant publication bias was found in this analysis according to Funnel plots and Begg's tests. Although subgroup analyses were conducted in the RP and RT groups, significant heterogeneity still existed in some subgroups. The relevant results indicated that these factors were not potential sources of high heterogeneity.

Several potential limitations of our meta-analysis need to be addressed. First, all the included studies were retrospective cohort studies, and data extracted from those studies may have led to inherent potential bias as an unmeasured and uncontrolled confounder. Second, only papers in English and Chinese were selected, and thus some studies that were published in other languages may have otherwise been eligible. Therefore, both selection and publication bias are possible. Third, the pathological diagnosis of PCa and the detection method of PNI varied throughout the eligible studies. Collectively, these factors may promote significant heterogeneity. Fourth, substantial heterogeneity was identified across the studies, and although subgroup analyses were conducted to explore the source of the heterogeneity, heterogeneity still existed in certain categories of analysis. Thus, our results should be interpreted with caution.

Conclusions {#Sec13}
===========

To conclude, despite the limitations listed above, this meta-analysis suggested the prognostic and clinicopathological importance of PNI in PCa. The results demonstrated that the presence of PNI is associated with a high risk of BCR whether the patient undergoes RP or RT. Since BCR has been reported to lead to distant metastasis and cancer death \[[@CR31]\], we suggested that some patients with PCa and PNI may benefit from adjuvant local or systemic therapy. However, more randomized controlled trials with standardized methods and long-term follow-up are needed to verify our results.
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